Updates: Update - Page 2
Covid-19 action plan – A message to our customers, collaboration partners & colleagues
As we all come to terms with the extraordinary and rapidly changing global situation caused by Covid-19, I would like to update you on the plans we have in…
Read update
Newcells Biotech technology: the fight against antibacterial resistance
Antibacterial resistance is an ever-increasing concern for today’s society. As more bacterial strains become resistant to greater numbers of antibiotics, we could see modern-day healthcare rewind back to the…
Read update
WHO WE ARE
A passionate, rigorous and dedicated team of scientists who deliver the highest quality services and products. Your reliable and knowledgeable partner.
Read updateWHY WE DO IT
Our purpose is to bridge the gap between scientific discovery and patients. We make a difference by providing better predictions of clinical outcomes.
Read updateHOW WE DO IT
Using our expertise in induced pluripotent stem cells (iPSCs), cellular physiology and organoid technology, we build functional pre-clinical in vitro models of kidney, retina, liver and lung. We engineer…
Read updateWHAT WE DO
Learning from structures in the body, we recreate functional 3D in vitro models through innovation and science. Our models incorporate the “best biology” and are predictive of new drugs’…
Read update
Looking forward: A year in review
2018 has been a significant year for Newcells Biotech. We have secured substantial investment, launched new, ground-breaking products, attended global events and expanded our every growing team. Here are some of…
Read update
Newcells head to Boston
International Trade Mission
Read update
ESTIV 2018 International Congress
Congress Round-Up The International Congress on In Vitro Toxicology (ESTIV2018) organised by the European Society of Toxicology was held in Berlin this October 2018. This year marks its 20th meeting, with the general theme of new…
Read update
22nd North American ISSX Meeting – Montréal, Canada (15th-19th July)
The meeting brings together individuals who are working on drug/xenobiotic research across a diverse range of fields such as clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal…
Read update
NB secures £2M investment from NVM Private Equity & Northstar Ventures to accelerate hiPSC growth
Founded on the technology of Prof Lyle Armstrong and Prof Majlinda Lako from Newcastle University, the company is at the forefront of the production and differentiation of human induced…
Read update
How the NHS Changed Our World: Tyneside’s Genetic Pioneers on BBC 1 (North East & Cumbria)
To watch the full video click here.
Read update
